<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Neurodegener</journal-id><journal-id journal-id-type="iso-abbrev">Mol Neurodegener</journal-id><journal-id journal-id-type="pmc-domain-id">425</journal-id><journal-id journal-id-type="pmc-domain">molneuro</journal-id><journal-title-group><journal-title>Molecular Neurodegeneration</journal-title></journal-title-group><issn pub-type="epub">1750-1326</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4929720</article-id><article-id pub-id-type="pmcid-ver">PMC4929720.1</article-id><article-id pub-id-type="pmcaid">4929720</article-id><article-id pub-id-type="pmcaiid">4929720</article-id><article-id pub-id-type="pmid">27363697</article-id><article-id pub-id-type="doi">10.1186/s13024-016-0115-2</article-id><article-id pub-id-type="publisher-id">115</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Immunotherapy targeting pyroglutamate-3 A&#946;: prospects and challenges</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cynis</surname><given-names initials="H">Holger</given-names></name><address><email>holger.cynis@izi.fraunhofer.de</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frost</surname><given-names initials="JL">Jeffrey L.</given-names></name><address><email>jeffrey.frost@umassmed.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crehan</surname><given-names initials="H">Helen</given-names></name><address><email>hcrehan@partners.org</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2983-7870</contrib-id><name name-style="western"><surname>Lemere</surname><given-names initials="CA">Cynthia A.</given-names></name><address><phone>+1 617-525-5214</phone><email>clemere@partners.org</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Ann Romney Center for Neurologic Diseases, Brigham and Women&#8217;s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB636, Boston, MA 02115 USA </aff><aff id="Aff2"><label/>Fraunhofer Institute for Cell Therapy and Immunology, Weinbergweg 22, 06120 Halle, Germany </aff><aff id="Aff3"><label/>University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01605 USA </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">263261</issue-id><elocation-id>48</elocation-id><history><date date-type="received"><day>26</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2016</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>06</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>02</day><month>07</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2016-07-02 20:43:47.837"><day>02</day><month>07</month><year>2016</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13024_2016_Article_115.pdf"/><abstract id="Abs1"><p>Immunization against amyloid-&#946; (A&#946;) peptides deposited in Alzheimer&#8217;s disease (AD) has shown considerable therapeutic effect in animal models however, the translation into human Alzheimer&#8217;s patients is challenging. In recent years, a number of promising A&#946; immunotherapy trials failed to reach primary study endpoints. Aside from uncertainties in the selection of patients and the start and duration of treatment, these results also suggest that the mechanisms underlying AD are still not fully understood. Thorough characterizations of protein aggregates in AD brain have revealed a conspicuous heterogeneity of A&#946; peptides enabling the study of the toxic potential of each of the major forms. One such form, amino-terminally truncated and modified pyroglutamate (pGlu)-3 A&#946; peptide appears to play a seminal role for disease initiation, qualifying it as novel target for immunotherapy approaches.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Amyloid-&#946;</kwd><kwd>Pyroglutamate-3 A&#946;</kwd><kwd>Immunotherapy</kwd><kwd>Vaccine</kwd><kwd>Glutaminyl cyclases</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Institutes of Health, NIH/NIA</institution></funding-source><award-id>RO1 AG040092</award-id><principal-award-recipient><name name-style="western"><surname>Lemere</surname><given-names>Cynthia A.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Alzheimer&#8217;s disease (AD) is the leading cause of dementia estimated to affect ~80&#8211;131.5 million individuals worldwide by the middle of the 21<sup>st</sup> century [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. AD is characterized by a progressive loss of memory accompanied by emotional changes, hallucinations, delusions and impaired social behavior leading to an increased need for around-the-clock care in the final stages of the disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. The disorder is considered to be developed spontaneously in the vast majority of individuals, although studies in monozygous twins suggest a strong genetic component [<xref ref-type="bibr" rid="CR4">4</xref>]. The average age of onset is within the 7<sup>th</sup> or 8<sup>th</sup> decade of life. AD is characterized by two pathological hallmarks, extracellular amyloid plaques composed of deposited &#946;-amyloid (A&#946;) peptides, and intraneuronal neurofibrillary tangles formed from hyperphosphorylated tau protein [<xref ref-type="bibr" rid="CR4">4</xref>]. In a low number of AD cases (&lt;1&#160;%) the disease is inherited in a dominant fashion. Most of the identified familial AD (FAD) mutations lie within the sequence of the amyloid precursor protein (APP) or in the presenilins, the proteolytic machinery that liberates A&#946; molecules [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The resulting alterations in APP processing or changes in the biophysical properties of the resulting A&#946; peptides, lead to an early onset of the disease most frequently developed within the 5<sup>th</sup> and 6<sup>th</sup> decade of life [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]; however, some rare mutations are able to cause a shift of the age of onset as early as the 3<sup>rd</sup> decade of life [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, the accumulation of A&#946; aggregates plays an early and essential role in AD and is the target for immunotherapy approaches. However, most A&#946; immunization trials have failed thus far. We suggest that one of the possible contributing factors for study failure might be the A&#946; forms being targeted by the vaccines and/or antibodies. Previous studies have revealed a heterogeneous mixture of different A&#946; species in human brain parenchyma with differing amyloidogenic potential. An N-terminally truncated and pyroglutamate-modified A&#946; variant, pGlu-3 A&#946;, has gained attention due to its exceptionally high amyloidogeneity and neurotoxicity. Here, we discuss this variant and its potential as a target for A&#946; immunization in the light of recent developments in several general A&#946; immunotherapy trials.</p></sec><sec id="Sec2"><title>Main Text</title><sec id="Sec3"><title>The origin and pathobiology of pGlu-3 A&#946;</title><p>One major pathologic hallmark of AD is the extracellular amyloid plaque. Amyloid plaque deposits were among the fundamental findings when Alois Alzheimer first described the neurologic disorder later named after him. For a long time the nature of the plaque was unknown until it was found that a protein fragment called amyloid-&#946; (A&#946;), generated by cleavage of the large transmembrane protein, amyloid precursor protein (APP), was its main component [<xref ref-type="bibr" rid="CR9">9</xref>]. The generation of A&#946; peptides is orchestrated by the consecutive cleavage of APP by proteases termed &#946;- and &#947;-secretase. Later, BACE I was identified to be the major &#946;-secretase while a protein complex composed of presenilin 1 (PS1), nicastrin, APH-1 and PEN-2 was identified as &#947;-secretase [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The major A&#946; isoforms possess a length of 40 (A&#946;40) and 42 (A&#946;42) amino acids, respectively. Following &#946;-secretase cleavage of the A&#946; N-terminus, the C-terminal isoforms are generated by intramembrane proteolysis by the &#947;-secretase complex [<xref ref-type="bibr" rid="CR12">12</xref>]. The major N-terminal form of A&#946; was shown to start with an aspartic acid (amino acid 597 of the 695 amino acids long APP isoform) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>]. This is in line with the cleavage pattern of BACE I, preferentially leading to the liberation of A&#946; peptides starting at Asp-1 [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. However, reports published shortly after the seminal work by Glenner and Wong [<xref ref-type="bibr" rid="CR16">16</xref>] identifying A&#946; protein, noted truncated and blocked N-termini on A&#946; molecules isolated from AD brain [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Later it became evident that N-terminal truncated and pGlu-modified A&#946; species (pGlu-3 A&#946;) in particular are present in large quantities in human AD brain, which is in contrast to the vast majority of AD mouse models, where full-length peptides are the predominant A&#946; species [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Depending on the method of detection, the relative amount of pGlu-3 A&#946; in human brain was described between 1&#160;% as measured by ELISA [<xref ref-type="bibr" rid="CR21">21</xref>] and 27&#160;% as measured by mass spectrometry [<xref ref-type="bibr" rid="CR22">22</xref>]. This was recently corroborated by detailed analysis of regional and temporal appearance of general A&#946; and pGlu-3 A&#946; in sporadic AD, animal models of spontaneous cerebral amyloidosis and transgenic mouse models. In the human AD brain, pGlu-3 A&#946; is a major species in diffuse and compacted plaques as well as cerebral amyloid angiopathy, whereas in common transgenic mouse models, pGlu-3 A&#946; is deposited only in a subset of compacted plaques and vascular amyloid in later stages of cerebral amyloidosis [<xref ref-type="bibr" rid="CR23">23</xref>]. Since mouse models have been extensively used in AD research thus far, the low frequency of pGlu-3 A&#946; in such models may have hampered investigations on the contribution of these peptides to amyloid pathology.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Targeting site for pGlu-3 A&#946;-specific therapeutic antibodies. Full-length A&#946; is comprised of 40 or 42 amino acids (A&#946; 1-40/42). The six N-terminal amino acids of A&#946; are depicted by one-letter code of amino acids and chemical structure. pGlu-3 A&#946; is a truncated and post-translationally modified variant generated by catalysis of yet unknown proteases and QC/isoQC to convert an N-terminal glutamate residue into a cyclic 5-oxo-proline ring structure (&#8220;pGlu&#8221;, &#8220;pE&#8221;). Thereby, a neoepitope is generated that is not present in full-length A&#946; molecules. The interaction site of pGlu-3 A&#946;-specific antibodies is represented by the line drawn around the pGlu-modified A&#946; N-terminus</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13024_2016_115_Fig1_HTML.jpg"/></fig></p><p>The production of truncated pGlu-3 A&#946; peptides is not fully understood. The identified &#946;-secretase, BACE 1, preferentially generates full-length A&#946; peptides starting at Asp-1 and to a lesser extent N-terminally truncated Glu-11 A&#946; [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, the generation of pGlu-3 A&#946; from Asp-1 A&#946; requires 2 additional modifying steps, N-terminal proteolysis of the first two A&#946; amino acids followed by cyclization of glutamate at position 3. The mechanism of glutamate cyclization has recently been uncovered and Glutaminyl Cyclase (QC), an aminoacyltransferase was identified as the responsible enzyme <italic toggle="yes">in vitro</italic> [<xref ref-type="bibr" rid="CR24">24</xref>] and <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="CR21">21</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). This was unexpected, as QC preferentially converts N-terminal glutamine residues into pGlu, whereas the precursor in A&#946; is glutamate. However, the substrate specificity of QC is slightly relaxed and QC is also capable of converting, e.g. N-terminal &#946;-homoglutamine [<xref ref-type="bibr" rid="CR25">25</xref>] finally leading to the discovery of glutamate cyclization by QC under mildly acidic conditions [<xref ref-type="bibr" rid="CR24">24</xref>]. QC converts glutamate residues at a 3 orders-of-magnitude lower rate constant than N-terminal glutamine residues, but the rate enhancement of QC-mediated catalysis compared to spontaneous cyclization in water is only 2 orders-of-magnitude lower for N-terminal glutamate compared to glutamine. Therefore, the specificity for its primary substrate glutamine is only modest and in turn, QCs catalytic contribution to the generation of pathologic A&#946; peptides formed from a glutamate precursor can be considered as substantial [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>In contrast, the mechanism of N-terminal truncation remains elusive. It has been suggested that Aminopeptidase A contributes to the N-terminal truncation of full-length A&#946; peptides [<xref ref-type="bibr" rid="CR27">27</xref>] but direct liberation of truncated A&#946; peptides by alternative pathways have also been suggested [<xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref>].</p><p>Compared to full-length A&#946;1-40 and A&#946;1-42, pGlu-3 A&#946; possesses a higher amyloidogeneity and toxicity. This is reflected by a higher surface hydrophobicity, lower solubility and a strikingly different appearance of fibrils by electron microscopy compared to A&#946;1-40 or A&#946;1-42 [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Most interestingly, pGlu-3 A&#946; has been suggested to act as a seed for template-induced misfolding, reminiscent of prions [<xref ref-type="bibr" rid="CR34">34</xref>]. Co-oligomerization of a low amount of pGlu-3 A&#946; peptides with an excess of full-length A&#946;1-42 gave rise to the same cytotoxic A&#946; species as oligomerization of pGlu-3 A&#946; alone. These results suggest that pGlu-3 A&#946; oligomers transfer their cytotoxic nature to A&#946;1-42 peptides even when present in small quantities and therefore propagate the generation of cytotoxic oligomers in a prion-like fashion [<xref ref-type="bibr" rid="CR34">34</xref>]. As a consequence, pGlu-3 A&#946; molecules might play an important role for early neuronal toxicity observed in AD. Indeed, pGlu-3 A&#946; peptides are more toxic to neuronal and glial cultures than full-length A&#946; peptides [<xref ref-type="bibr" rid="CR35">35</xref>]. In addition, overexpression of pGlu-3 A&#946; in mice leads to neuron loss [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], which is in stark contrast to the overexpression of A&#946;1-40 or 1-42. Both full-length peptides failed to produce an overt neurotoxic phenotype aside from plaque deposition in mice [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. However, the molecular basis for the higher toxicity of pGlu-3 A&#946; is only poorly understood. A potential mechanism suggests that larger pGlu-3 A&#946; oligomers are formed through faster aggregation kinetics (compared to full-length A&#946; peptides) and subsequently insert into membranes, forming pore-like structures. This might lead to higher ion permeability and altered membrane properties, which ultimately could result in a loss of cell homeostasis [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. In addition, pGlu-3 A&#946; was only recently described to enhance lipid peroxidation in primary cortical mouse neurons, to trigger Ca<sup>2+</sup> influx and to facilitate the loss of plasma membrane integrity [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>Consequently, pGlu-3 A&#946; is an emerging target for immunotherapy approaches in AD, which have previously shown considerable effects in preclinical animal models [<xref ref-type="bibr" rid="CR43">43</xref>]. In this regard, the relatively novel concept of anti-pGlu-3 A&#946; immunization may benefit from a decade of experiences with immunotherapy trials against other A&#946; forms.</p></sec><sec id="Sec4"><title>Immunotherapy against A&#946;</title><p>Immunotherapy against A&#946; peptides in AD includes both active and passive immunization approaches [<xref ref-type="bibr" rid="CR44">44</xref>]. The goal of active A&#946; vaccines is to elicit a strong cellular and humoral antibody response through B- and T-cells. This is commonly achieved by using an antigen, either alone or conjugated to a non-self T helper cell epitope, to direct the immune response towards production of anti-A&#946; antibodies, combined with an adjuvant to induce high antibody titers. One main advantage of this approach is a sustained immune response that is refined through affinity maturation, thus requiring a limited number of immunizations and making it ideal for distribution in a large patient population. However, caveats are the possibility of an induction of a deleterious inflammatory T-cell response that requires time to quench. In addition, the production of polyclonal antibodies makes this strategy less preferable if specific targeting of a particular isoform or epitope of A&#946; is desired. Finally, age-related immunosenescence in the elderly render AD patients poor antibody responders.</p><p>Passive immunotherapeutic approaches against A&#946; can be utilized to overcome some of these limitations. With direct injection of monoclonal antibodies, immunosenescence is not an issue and specific targeting of a particular epitope or isoform of A&#946; is easily achieved. Furthermore, if adverse events should ensue, monoclonal antibody infusions can be discontinued. Drawbacks to this method include sustained production costs associated with generating massive amounts of humanized monoclonal antibodies, continued antibody infusions requiring many visits to the doctor&#8217;s office, and the potential of a patient developing anti-antibodies causing a neutralizing effect towards the exogenous antibody injections.</p></sec><sec id="Sec5"><title>Recent active A&#946; vaccine trials</title><p>The promising idea of active vaccination against A&#946; peptides came to a sudden halt in 2002, when the first active vaccination trial in humans (AN1792) caused abnormalities described as a form of meningoencephalitis, likely an autoimmune reaction, possibly to A&#946; in blood vessel walls, in approximately 6&#160;% of enrolled moderate-to-severe AD patients [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. The side effects included the presence of lymphocytes in the CSF and focal white matter abnormalities on imaging [<xref ref-type="bibr" rid="CR45">45</xref>]. While the exact causes of these adverse events were never definitively understood, probable causes may have been the use of full-length A&#946;1-42 as an the immunogen, which has since been shown to display several T-cell epitopes particularly in the region between amino acids 15 and 42, the use of Q21, a highly Th1 biased adjuvant, or the formulation change of adding polysorbate 80 for stability [<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref>]. Besides the observed adverse events, autopsies of cases enrolled in AN1792 showed evidence of amyloid removal, although without any improvement in dementia [<xref ref-type="bibr" rid="CR50">50</xref>]. Therefore, second-generation active A&#946; vaccines are under development to overcome the pitfalls observed in the AN1792 trial. Active vaccines brought to early stage clinical trials aim to exclusively target B-cell epitopes to generate a robust humoral response, while reducing the chance of an autoimmune T-cell pro-inflammatory response through the use of N-terminal A&#946; fragments, mimotope and neoepitope vaccines, as well as phage and virus-like particle vaccines [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p>In 2013, Pfizer and Janssen completed phase II clinical trials in 360 mild to moderate AD patients testing the safety and efficacy of their ACC-001 (vanutide cridificar) active vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>), which consists of an A&#946; N-terminal fragment (A&#946; 1-7) conjugated to an immuno-stimulatory carrier protein with and without QS21 as adjuvant [<xref ref-type="bibr" rid="CR51">51</xref>]. Recently, the safety outcome of a study in Japanese subjects with mild to moderate AD was published [<xref ref-type="bibr" rid="CR52">52</xref>]. High antibody titers were reported along with a number of mild to severe adverse events [<xref ref-type="bibr" rid="CR52">52</xref>]. The clinical development of this treatment was discontinued, in 2015, for reasons that have not been disclosed.</p><p>Furthermore, in 2012, Novartis reported its phase I clinical data in patients with mild to moderate AD immunized with CAD106, a novel vaccine consisting of multiple copies of A&#946; 1-6 coupled to a coat protein of bacteriophage Q&#946;. After three subcutaneous injections of 50&#160;&#956;g CAD106 in cohort 1 or 150&#160;&#956;g CAD106 in cohort 2, 67 and 82&#160;%, respectively, of treated patients had generated significant anti-A&#946; serum antibodies levels classifying them as responders. While no alterations in CSF A&#946; or whole brain MRI volume were observed between CAD106 and placebo groups, these studies were not statistically powered to detect changes in biomarkers [<xref ref-type="bibr" rid="CR53">53</xref>]. Subsequent phase II clinical trials with CAD106 have been completed and were first reported at the 2014 Alzheimer&#8217;s Association International Conference (AAIC) in Copenhagen, Denmark. There, it was reported, that strong serological responders bound less florbetapir at 78&#160;weeks than at baseline. No changes in CSF A&#946; were observed, but CSF p-tau declined in strong antibody responders (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>). Additional phase II clinical data were reported only recently [<xref ref-type="bibr" rid="CR54">54</xref>]. Immunization of patients using 150&#160;&#956;g CAD106 led to 63.8&#160;% serological responders. In addition, 74.5&#160;% adverse events in treated patients compared to 63.3&#160;% adverse events in placebo group were reported. Amyloid-related imaging abnormalities (ARIA) corresponding to microhemorrhages were observed in 3 patients treated with CAD106. No vasogenic edemas were observed [<xref ref-type="bibr" rid="CR54">54</xref>]. Novartis and the Banner Health Institute have begun phase II/III trials testing this novel vaccine with a BACE I inhibitor in pre-symptomatic, cognitively healthy adults, who have two copies of the ApoE4 gene, making them more at risk of developing AD, in a trial known as the Alzheimer&#8217;s Prevention Initiative APOE4 trial, expected to reach completion in 2023 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>).</p><p>Also, currently in clinical phase I/II trials is AC Immune&#8217;s ACI-24 liposome-based vaccine using A&#946;1-15, which aims to produce &#946;-sheet conformation-specific antibodies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acimmune.com">www.acimmune.com</ext-link>). AC Immune, together with the LuMind Research Down Syndrome Foundation, have brought this vaccine into phase I trials in 24 adults with Trisomy 21-positive Down Syndrome, the results of which are expected in 2019 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>). In addition, UB-311 (United Biomedical), targeting A&#946;1-14, has shown safety and efficacy in phase I clinical trials with a phase II study currently recruiting patients with mild AD (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>) and V950 from Merck, an N-terminal A&#946; fragment conjugated to an aluminum-containing adjuvant with or without ISCOMATRIX, has completed a phase I clinical trial.</p><p>Finally, an active vaccine developed by AFFiRiS AG, Austria stimulating an immune response against A&#946; by short peptides obtained by molecular mimicry (&#8220;mimotopes&#8221;) [<xref ref-type="bibr" rid="CR55">55</xref>] has completed phase II clinical trials. Their front-runner AD02 stimulates an immune response directed towards the N-terminus of unmodified A&#946; species (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>). At a press briefing in June 2014, AFFiRiS reported first results on the efficacy of AD02 showing that AD02 did not reach primary or secondary outcome measures (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>). According to AFFiRiS (12th International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurologic Disorders, AD/PD 2015, Nice), placebo-treated patients showed less cognitive decline accompanied by less hippocampal shrinkage than AD02-treated patient. Whether the ingredients of the placebo formulation are indeed responsible for the observed effects remains to be determined. Nevertheless, the same formulation was also used for application of AD02, confusing the potential causes of this trial failure (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>).</p></sec><sec id="Sec6"><title>Latest developments in passive A&#946; immunotherapy</title><p>Following the termination of the AN1792 trial, significant effort has gone into the development and testing of monoclonal antibodies for passive A&#946; immunization. The first antibody in clinical trials, bapineuzumab (Janssen and Pfizer), is the humanized version of 3D6, an IgG1 mouse monoclonal specific for an N-terminal A&#946; epitope (A&#946;1-5) and it only recognizes A&#946; peptides with an aspartic acid residue at the N-terminus [<xref ref-type="bibr" rid="CR56">56</xref>]. Although phase II clinical trials in mild-to-moderate AD did not initially present clear clinical benefits, <italic toggle="yes">post-hoc</italic> analysis revealed that a subgroup of ApoE4 non-carriers showed some evidence of clinical improvement. Furthermore, 12/124 (9.7&#160;%) of bapineuzumab-treated patients experienced transient and reversible edema [also known as ARIA-E], which was more frequent in ApoE4 carriers with one copy of the allele (7.1&#160;%) and two copies of the allele (33.3&#160;%) compared to non-carriers (4.3&#160;%). In addition, 11/12 edema cases occurred at a dose &gt;1&#160;mg/kg [<xref ref-type="bibr" rid="CR57">57</xref>]. Whether the observed edema is vasogenic or due to other mechanisms such as microglial activation requires further studies. Target engagement detected by <sup>11</sup>C-PiB PET imaging showed evidence for a stabilization of A&#946; burden in bapineuzumab-treated subjects compared to an increase in the placebo-treated individuals [<xref ref-type="bibr" rid="CR58">58</xref>]. These findings and modest clinical benefits warranted continued evaluation in phase III trials. Unfortunately, two large phase III clinical trials reported no significant clinical benefits, which led to the termination of all phase III bapineuzumab clinical trials. Recent biochemical analyses of the brains from 3 patients treated with bapineuzumab showed a trend for reduction in A&#946;42 accompanied by an increase in A&#946;40 leading to an overall reduction in the A&#946;42/40 ratio. These findings highlight a dynamic homeostatic balance of A&#946;, obviously altered by bapineuzumab treatment [<xref ref-type="bibr" rid="CR59">59</xref>]. In addition, AAB-003, a derivative of Bapineuzumab with altered effector function was tested in Phase I studies with results pending (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>).</p><p>Eli Lilly&#8217;s solanezumab is the humanized version of m266, an IgG1 monoclonal antibody that recognizes an epitope within A&#946;16-24. It is purported to preferentially recognize soluble A&#946; species and not fibrillar A&#946; and has been shown to increase both plasma and CSF A&#946; [<xref ref-type="bibr" rid="CR60">60</xref>]. Solanezumab was tested in phase III clinical trials and failed to show significant improvement in primary outcomes in the phase 3 trials, EXPEDITION 1 and EXPEDITION 2 [<xref ref-type="bibr" rid="CR61">61</xref>]. Secondary analysis in pooled subjects from both trials with mild AD showed less cognitive and functional decline when treated with solanezumab compared to placebo. In contrast, patients with moderate AD did not benefit from solanezumab treatment [<xref ref-type="bibr" rid="CR62">62</xref>]. Unlike bapineuzumab, solanezumab has not been associated with ARIA-E or microhemorrhages [<xref ref-type="bibr" rid="CR60">60</xref>] and is well tolerated at doses up to 400&#160;mg administered weekly. An additional phase III study testing solanezumab at 400&#160;mg every 4 weeks for 76&#160;weeks in mild AD patients (EXPEDITION III), is currently ongoing and expected to reach completion in 2018 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>).</p><p>Most recently, aducanumab, a co-development of Neurimmune (Switzerland) and Biogen (USA) has gained much attention. Aducanumab (BIIB037) results from reverse translational medicine and is not a humanized mouse monoclonal antibody. Instead, it is a fully human IgG1 monoclonal antibody isolated from healthy aged donors representing cognitively healthy aging (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>). As presented at the 11<sup>th</sup> International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurological Disorders held in 2013 in Florence, Italy, aducanumab binds fibrillar amyloid and is able to reduce plaque burden in AD mice. Aducanumab was tested in prodromal or mild AD and showed a dose-dependent reduction of A&#946;-PET signal almost to threshold levels and slowing of cognitive decline at the highest dose (10&#160;mg/kg) as presented at AD/PD 2015 in Nice and the Alzheimer&#8217;s Association International Conference (AAIC) 2015 in Washington DC. The observed effect on cognitive decline was dose-dependent. ARIA-E was reported to increase with dose and ApoE4 carriage with 55&#160;% incidence in homozygous ApoE4 carriers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>). Nevertheless, this represents a breakthrough in AD immunotherapy and the data encouraged the development team to take aducanumab directly to phase III clinical studies.</p><p>In addition to the clinical development of monoclonal A&#946; antibodies, consortia were established to study the effect of preventive passive immunization in different study populations. In this regard, the &#8220;Dominantly Inherited Alzheimer&#8217;s Network&#8221; (DIAN) is testing treatments in patients with FAD mutations that puts them at a greater risk for developing AD than the general population. The monoclonal antibodies solanezumab (Lilly) and gantenerumab (Roche) were chosen as the two investigational antibodies. Gantenerumab, an IgG1 antibody, recognizes two epitopes in A&#946;. One lies within the N-terminus and another within the mid-region of A&#946;. Gantenerumab was further shown to preferentially bind fibrillar A&#946; [<xref ref-type="bibr" rid="CR63">63</xref>]. This study is scheduled for completion at the end of 2016.</p><p>Furthermore, the &#8220;Alzheimer&#8217;s Prevention Initiative&#8221; (API) is currently enrolling 300 Columbian individuals harboring an autosomal-dominant E280A PS1 mutation, which has been associated with early-onset AD [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Because of its IgG4 backbone designed to engage microglial-mediated phagocytosis of A&#946; but not to induce a pro-inflammatory response, crenezumab (Genentech) has been selected. Crenezumab is the humanized version of antibody mMABT generated by immunizing mice with a liposome-coupled N-terminal fragment of A&#946; (A&#946; 1-15) termed AC-01 by the Switzerland-based company AC Immune [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Crenezumab was described to bind different aggregated forms of A&#946;, including oligomers and fibrils and to possess a low affinity for A&#946; monomers [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p>Finally, unlike the two aforementioned initiatives in FAD subjects, the &#8220;Anti-Amyloid Treatment for Asymptomatic Alzheimer&#8217;s Disease&#8221; (A4) is enrolling 1000 subjects between 65&#8211;85 years of age w/o dominantly inherited early onset AD mutations, who exhibit amyloid in brain by PET imaging but are otherwise cognitively normal. This study targets people that are at risk for developing sporadic AD and represents the majority of the AD population. Because of its known safety profile and evidence of modest cognitive benefit in mild AD patients, solanezumab was chosen for the A4 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>).</p></sec><sec id="Sec7"><title>Rationale for immunization against pGlu-3 A&#946;</title><p>Most of the A&#946; immunotherapy clinical trials have not reached primary endpoints thus far, although some positive effects were observed in <italic toggle="yes">post-hoc</italic> analyses, e.g. in the Solanezumab Expedition Trials. Aside from known problems with selecting the right study population and the optimal cognitive stage of a patient for starting treatment, current immunotherapy strategies may not be targeting A&#946; peptides with high toxic potential such as pGlu-3 A&#946; [<xref ref-type="bibr" rid="CR34">34</xref>]. In this regard, pGlu-3 A&#946; appears to be an attractive novel target for A&#946; vaccination approaches as A&#946;1-40 and A&#946;1-42 are products of normal APP turnover [<xref ref-type="bibr" rid="CR68">68</xref>]. In addition, A&#946; is produced at similar levels by young and aged individuals [<xref ref-type="bibr" rid="CR69">69</xref>]. Its production rate in healthy volunteers and AD patients does not significantly differ, e.g. A&#946;42 is generated with a rate of 6.7&#160;%/h in non-AD and 6.6&#160;%/h in AD patients as measured by the increase of <sup>13</sup>C<sub>6</sub>-leucine labeled A&#946; in CSF over time [<xref ref-type="bibr" rid="CR70">70</xref>]. Therefore, it is reasonable to consider A&#946;1-40 and A&#946;1-42 as physiologic peptides, although their exact biologic role is still not well understood. Recent investigations have shown an anti-microbial activity of A&#946; as well as an importance for neuronal physiology [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Thus, active vaccination against full-length A&#946; peptides early in life might eliminate an important molecule of innate immunity and neuronal physiology with unknown outcome.</p><p>In contrast to the physiologic generation of A&#946;1-40 and A&#946;1-42 peptides, pGlu-3 A&#946;, the result of a significant side-reaction of QC, has a dramatic influence on the amyloidogeneity and toxicity of the A&#946; molecule. Therefore, pGlu-3 A&#946; represents a solely non-physiologic neoepitope (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) that could be targeted by different immunotherapy approaches, sparing the presumably physiologic A&#946; molecules 1&#8211;40 and 1&#8211;42.</p></sec><sec id="Sec8"><title>Active vaccination against pGlu-3 A&#946;</title><p>The development of second-generation active vaccines was initiated after failure of the AN1792 trial, however clinical testing has not caught up with extent of passive immunization clinical studies performed by peripheral application of humanized anti-A&#946; antibodies. Thus, the reports on active vaccination against pGlu-3 A&#946; are scarce and publicly reported clinical development is currently limited to a single biopharmaceutical company, AFFiRiS AG (Austria). Here, the active pGlu-3 A&#946; vaccine (&#8220;mimotope&#8221;) was obtained by molecular mimicry resulting in an unrelated peptide stimulating antibody production against pGlu-3 A&#946; (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR55">55</xref>]. This strategy circumvents a T-cell response suspected of causing clinical side effects in the AN1792 trial. Although no peer-reviewed publications are available for the preclinical testing of anti-pGlu-3 A&#946; mimotopes, according to a published patent, the company claims a 38&#160;% reduction in the area occupied by amyloid plaques in Tg2576 mice treated (s.c.) over 6&#160;months using an anti-pGlu-3 A&#946; mimotope with aluminum hydroxide (ALUM) as an adjuvant. The mice were sacrificed at 13&#160;months of age and plaque area was determined by an A&#946;40/42-specific antibody (Mandler M. <italic toggle="yes">et al</italic>. (2011) US Patent Application No: 20110097351). A Phase 1 clinical trial in mild AD patients of the active vaccine including the pGlu-3 A&#946; mimotope and alum adjuvant, AD03, was completed in 2011 with promising results, followed by a Phase 1b study that was terminated in 2013 due to organizational reasons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>). The outcome of the study has not been disclosed thus far.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Summary of preclinical results obtained by active and passive vaccination</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Ag/Ab</th><th colspan="1" rowspan="1">AD Model</th><th colspan="1" rowspan="1">Treatment</th><th colspan="1" rowspan="1">Effect</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Active vaccination</td></tr><tr><td colspan="1" rowspan="1">pGlu-3 mimotope</td><td colspan="1" rowspan="1">Tg2576</td><td colspan="1" rowspan="1">Preventive</td><td colspan="1" rowspan="1">Reduced plaques</td><td colspan="1" rowspan="1">USPTO No.: 20110097351</td></tr><tr><td colspan="1" rowspan="1">pGlu-3-9-KLH</td><td colspan="1" rowspan="1">J20</td><td colspan="1" rowspan="1">Preventive</td><td colspan="1" rowspan="1">Reduced plaques</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR73">73</xref>]</td></tr><tr><td colspan="1" rowspan="1">pGlu-3 A&#946;42</td><td colspan="1" rowspan="1">Rabbit (WT)</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td colspan="5" rowspan="1">Passive vaccination</td></tr><tr><td colspan="1" rowspan="1">9D5</td><td colspan="1" rowspan="1">5XFAD</td><td colspan="1" rowspan="1">Preventive</td><td colspan="1" rowspan="1">Reduced plaques and A&#946; peptides</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR76">76</xref>]</td></tr><tr><td colspan="1" rowspan="1">07/1</td><td colspan="1" rowspan="1">APP/PS1&#916;E9</td><td colspan="1" rowspan="1">Preventive &amp; Therapeutic</td><td colspan="1" rowspan="1">Reduced plaques; no change in A&#946; peptides</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR77">77</xref>&#8211;<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td colspan="1" rowspan="1">mE8</td><td colspan="1" rowspan="1">PDAPP</td><td colspan="1" rowspan="1">Therapeutic</td><td colspan="1" rowspan="1">No change in plaques; reduced A&#946; peptides</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR83">83</xref>]</td></tr></tbody></table><table-wrap-foot><p>
<italic toggle="yes">Ag</italic> Antigen, <italic toggle="yes">Ab</italic> Antibody, <italic toggle="yes">Ref</italic>. Reference, <italic toggle="yes">USPTO</italic> US Patent and Trademark Office</p></table-wrap-foot></table-wrap></p><p>At the Society for Neuroscience meeting held in San Diego in 2010, our own group reported the active vaccination of 6-month-old J20 mice with the N-terminal A&#946; fragment pGlu-3&#8211;9 coupled to KLH in comparison to an aged 3:1 mixture of A&#946;1-40 and A&#946;1-42, each with CFA/IFA adjuvant (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). J20 mice first start to develop pGlu-3 A&#946; containing plaques at 6&#160;months of age, albeit in low quantities [<xref ref-type="bibr" rid="CR20">20</xref>]. Mice were immunized (i.p.) on days 0, 14 and 28 followed by monthly injections for 8&#160;months and generated high titers of antibodies specific for the N-terminus of their respective antigens. Both vaccines resulted in a significant reduction of amyloid plaques, indicating that pGlu-3 A&#946;-targeted active immunization prevented deposition of both pGlu-3 A&#946; and general A&#946; with heterogeneous N-termini [<xref ref-type="bibr" rid="CR73">73</xref>]. This underlines the seeding capacity of pGlu-3 A&#946; and is in line with observations made by application of QC-specific inhibitors preventing pGlu-3 A&#946; formation [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Finally, active vaccination of rabbits using pGlu-3 A&#946;42 resulted in antibodies exclusively detecting this A&#946; isoform (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). No cross-reactivity was observed to A&#946;1-42 or pGlu-11 A&#946; [<xref ref-type="bibr" rid="CR74">74</xref>]. The immuno-dominant region of pGlu-3 A&#946; was identified within the N-terminus with no cross-reactivity to unmodified peptides starting with N-terminal glutamate [<xref ref-type="bibr" rid="CR74">74</xref>]. This is in contrast to active vaccination using A&#946;1-40 or A&#946;1-42, where the immuno-dominant epitope was represented by the amino acid sequence EFRH in the N-terminal region of full-length A&#946; [<xref ref-type="bibr" rid="CR75">75</xref>]. These data are corroborated by our own observations wherein immunization with pGlu-3&#8211;9-KLH dominantly produced pGlu-3 A&#946; specific antibodies whereas immunization with A&#946;1-40/42 produced N-terminal (A&#946; 1-15) specific antibodies. Aside from AFFiRiS&#8217;s AD03 mimotope vaccine, as far as we are aware, no other active anti-pGlu-3 A&#946; vaccine has progressed to clinical development to date.</p></sec><sec id="Sec9"><title>Passive immunization against pGlu-3 A&#946;</title><p>Passive anti-pGlu-3 A&#946; immunotherapy has been more frequently reported in the literature than active vaccination although the total number of publications is still very low. The first report on passive pGlu-3 A&#946; immunotherapy was published in 2010 [<xref ref-type="bibr" rid="CR76">76</xref>]. Thomas Bayer at the University of Goettingen&#160;(Germany) generated a novel IgG2b monoclonal antibody (9D5) preferentially targeting oligomeric aggregates of pGlu-3 A&#946; (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) and demonstrated that passive immunization (i.p.) of 250&#160;&#956;g 9D5 in 4.5-month-old 5XFAD mice over 6&#160;weeks reduced hippocampal and cortical total A&#946;, A&#946;40, A&#946;42 and pGlu-3 A&#946; plaque load and intracellular pGlu-3 A&#946; oligomers [<xref ref-type="bibr" rid="CR76">76</xref>]. The study further showed a significant reduction of pGlu-3 A&#946; in TBS and SDS fraction of brain lysates detected by ELISA. 5XFAD mice display general A&#946; deposition as early as 1.5&#160;months of age in cortical layer V and the subiculum. Detection of pGlu-3 A&#946; starts at 4&#160;months of age in focal plaques throughout cortical layer V and the subiculum, followed by detection in the granule cell layer of the dentate gyrus at 6&#160;months of age, and pGlu-3 A&#946; positive focal deposits throughout the entire brain at 9&#8211;12 months of age [<xref ref-type="bibr" rid="CR23">23</xref>]. Therefore, the study published by Bayer and colleagues started treatment around the onset of first pGlu-3 A&#946; deposition but after the onset of general A&#946; deposition and therefore, can be considered a prevention trial.</p><p>Two pilot studies published in 2012 by our own lab further strengthened the feasibility of passive pGlu-3 A&#946; immunization (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR77">77</xref>]. Here, APP/PS1&#916;E9 mice underwent preventive and therapeutic passive immunization using a novel pGlu-3 A&#946; specific antibody (07/1, IgG1) developed by Probiodrug AG (Germany). In APP/PS1&#916;E9 mice, general A&#946; deposition starts at approximately 5&#160;months of age in the hippocampus with a subset of plaques also positive for pGlu-3 A&#946;. At 14&#160;months of age, pGlu-3 A&#946; is found in diffuse and focal deposits in cortex, hippocampus and cerebellum. By 24&#160;months of age, these mice display abundant pGlu-3 A&#946; immunoreactivity of plaques within hippocampus and a subset of plaques in the neocortex [<xref ref-type="bibr" rid="CR23">23</xref>]. The pilot prevention trial was started in mice at 5&#8211;6 months of age, at the onset of plaque deposition. Passive immunization (i.p.) with 200&#160;&#956;g of 07/1 over 32&#160;weeks resulted in a significant reduction in the deposition of general A&#946; and pGlu-3 A&#946; and Thioflavin S-positive fibrillar A&#946; in the hippocampus as detected by immunohistochemistry (IHC). In addition, significant reductions in general A&#946; and pGlu-3 A&#946; deposition were observed in the cerebellum, an area prone to plaque deposition in this model [<xref ref-type="bibr" rid="CR23">23</xref>]. In contrast to the study from Wirths et al. [<xref ref-type="bibr" rid="CR76">76</xref>], we observed no significant reduction of pGlu-3&#8211;42 or total A&#946;42 measured by ELISA in guanidine HCl-extracted hemibrains. The reduced plaque load observed in the pilot passive immunization prevention trial was further validated in a larger study by our lab in which cognitive performance of 07/1-vaccinated APP/PS1&#916;E9 mice was normalized to wildtype levels following treatment [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p>The pilot therapeutic trial in plaque-rich 23-month-old mice using weekly 07/1 antibody injections (200&#160;&#956;g) for 7&#160;weeks demonstrated a plaque-lowering effect [<xref ref-type="bibr" rid="CR77">77</xref>]. A more recent larger study from our lab has confirmed and extended these results to include behavioral analyses [<xref ref-type="bibr" rid="CR79">79</xref>&#8211;<xref ref-type="bibr" rid="CR81">81</xref>]. Interestingly, we demonstrated in our pilot studies a similar strong reduction of amyloid plaque load and fibrillar A&#946; in aged APP/PS1&#916;E9 mice immunized for only 7&#160;weeks compared to that in the prevention study over 32&#160;weeks in young mice. This was even more pronounced in the cerebellum, an area of late plaque deposition in this model, suggesting that the antibody may be most efficacious in preventing and/or removing newly deposited plaques. This result is consistent with the change in A&#946;40/42 ratio observed in patients immunized with bapineuzumab [<xref ref-type="bibr" rid="CR59">59</xref>], and suggests that passive immunization using a pGlu-3 A&#946; antibodies is able to change parameters of pathology long after the onset of amyloid deposition. Importantly, unlike previous reports that passive immunization with N-terminal A&#946; antibodies increased the incidence of microhemorrhages in aged APP23 mice [<xref ref-type="bibr" rid="CR82">82</xref>], we have observed no increase in microhemorrhages in 07/1 pGlu-3 A&#946;-immunized APP/PS1&#916;E9 mice to date.</p><p>A recent publication from researchers at Eli Lilly and Company described the effects of a novel pGlu-3 A&#946; specific IgG2a antibody (mE8) on A&#946; levels and plaque pathology in aged PDAPP mice (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR83">83</xref>]. The results were compared to the 3D6 IgG1 antibody, which represents the murine precursor of bapineuzumab. Aged PDAPP mice (23&#8211;24 months) were treated for 3&#160;months with 12.5&#160;mg/kg&#160;mE8 and 3D6. At the start of treatment the mice showed a similar proportion of pGlu-3-modified A&#946;42 as observed in human AD brain tissue. The applied dose translated into approximately 500&#160;&#956;g antibody/mouse, which is 2.5X the amount used in our own pilot study. DeMattos et al. were able to show a significant reduction of guanidine-HCl extractable A&#946;1-42 in hippocampus. The effect was dependent on the effector function of the respective IgG molecule, with mE8-IgG2a being more effective than mE8-IgG1. This was in line with the abilities of different mE8-IgG subclasses to stimulate <italic toggle="yes">ex vivo</italic> phagocytosis of A&#946; by primary murine microglia cells. The effect on A&#946;1-42 was less pronounced in cortex, where only treatment with mE8-IgG2a reached statistical significance. In addition, quantification of the total plaque area by immunohistochemical staining failed to show differences among the treatment groups although the authors reported a reduction of existing &#8220;plaque load&#8221; by mE8 treatment using biochemical measurements (ELISA) [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. This is in contrast to our published pilot study, where significant reductions in both general and pGlu-3 A&#946; labeled plaques were observed [<xref ref-type="bibr" rid="CR77">77</xref>]. More recently, Lilly reported at the Alzheimer&#8217;s Association International Conference held in Copenhagen in 2014 that co-treatment of mice with their pGlu-A&#946; specific antibody mE8 together with a BACE I-inhibitor cleared both compacted and diffuse plaques in aged PDAPP mice, suggesting that the BACE I inhibitor led to a reduction of diffuse plaques while the pGlu-A&#946; antibody to a reduction of compacted plaques. The combination cleared both types of amyloid deposits suggesting a synergistic effect of such combination therapy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.alzforum.org">www.alzforum.org</ext-link>). The clinical candidate is termed LY3002813 and an ongoing clinical phase 1 trial is aiming at determining safety and tolerability in up to 100 healthy participants as well as in subjects with MCI and mild to moderate AD patients (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>).</p></sec></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusions</title><p>AD brains contain considerable amounts of pGlu-3 A&#946; although absolute values differ between the methods used for quantification. Results obtained by ELISA showed that pGlu-3 A&#946;42 accounts for less than 1&#160;% of total A&#946;42 [<xref ref-type="bibr" rid="CR21">21</xref>]. Other studies using mass spectrometry calculated quantities of up to 27&#160;% of all A&#946; peptides to start with an N-terminal pGlu-residue in temporal cortex [<xref ref-type="bibr" rid="CR22">22</xref>]. In cotton wool plaques deposited in patients carrying the PS1 V261I mutation, N-truncated and pGlu-modified A&#946; peptides represent the major species [<xref ref-type="bibr" rid="CR6">6</xref>]. Therefore it is unclear, why pGlu-3 A&#946; peptides did not gain much attention. One explanation might be that the pGlu-modification was frequently considered as secondary reaction occurring later in disease progression [<xref ref-type="bibr" rid="CR84">84</xref>].</p><p>Although the absolute amount of deposited pGlu-3 A&#946; varies between different reports, preclinical studies aiming at reducing pGlu-3 A&#946; peptides in brains of AD-like mouse models have shown remarkable success. The ability to reduce general A&#946; deposition by pGlu-3 A&#946;-specific immunotherapy is comparable to the efficacy seen with immunization targeting full-length A&#946; [<xref ref-type="bibr" rid="CR83">83</xref>].</p><p>It has been suggested that pGlu-3 A&#946; is a seeding species for general A&#946; deposition. Furthermore, pGlu-3 A&#946; appears to cause template-induced misfolding of other A&#946; molecules already apparent in very low quantities [<xref ref-type="bibr" rid="CR34">34</xref>]. Active and passive immunization approaches as well as pharmacologic inhibition of pGlu-3 A&#946; formation by QC inhibitors in mouse models with considerable lower pGlu-3 A&#946; deposition compared to humans [<xref ref-type="bibr" rid="CR20">20</xref>] now substantiates these biophysical and cell biological studies [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Due to its nature as a by-product of a catalytic side-reaction of QC, pGlu-3 A&#946; further represents a true A&#946; neoepitope that only correlates with deleterious effects on brain physiology.</p><p>Despite these encouraging results, immunotherapy against pGlu-3 A&#946; faces similar challenges as approaches directed against other A&#946; isoforms. These include: (I) Passively administered pGlu-3 A&#946; antibodies need to efficiently cross the blood brain barrier to reach target molecules in the brain. (II) Treatment needs to be initiated as early as possible since active and passive immunization in patients already diagnosed with AD has been incapable of stopping disease progression thus far. (III) Active immunization against pGlu-3 A&#946; in AD patients would also face the problem of immunosenescence leading to a certain percentage of non-responders. (IV) The application of humanized monoclonal antibodies may induce an immune response against the treatment antibodies reducing their efficacy. (V) pGlu-3 A&#946; appears to be specifically present in brain parenchyma and absent in detectable amounts in body fluids such as CSF or plasma [<xref ref-type="bibr" rid="CR83">83</xref>]. Given its neurotoxic nature, it is unclear what adverse effects are to be expected when this exceptionally toxic variant is mobilized from deposits of PiB-positive individuals by A&#946; immunotherapy. On the other hand, the absence of detectable levels of pGlu-3 A&#946; in plasma may reduce peripheral saturation thereby allowing more antibodies for delivery to the brain parenchyma.</p><p>In the future, the current clinical trials (DIAN, API, A4) that aim to prevent AD symptoms in people at risk, will help to further illuminate the way for AD immunotherapy, including immunization targeting pGlu-3 A&#946;.</p></sec><sec id="Sec11"><title>Abbreviations</title><p>A4, Anti-Amyloid Treatment for Asymptomatic Alzheimer&#8217;s Disease; AAIC, Alzheimer&#8217;s Association International Conference; AD, Alzheimer&#8217;s disease; AD/PD, International Conference on Alzheimer&#8217;s Disease &amp; Parkinsons&#8217;s Disease; API, Alzheimer&#8217;s Prevention Initiative; ApoE4, Apolipoprotein E4 allele; APP, amyloid precursor protein; ARIA, amyloid-related imaging abnormalities; A&#946;, beta-amyloid peptide; BACE, beta-site APP cleaving enzyme; CFA, Complete Freund adjuvant; CSF, cerebrospinal fluid; DIAN, Dominantly Inherited Alzheimer&#8217;s Network; FAD, familial form of Alzheimer&#8217;s disease; IFA, incomplete Freund adjuvant; IgG, immunoglobulin G; KLH, keyhole limpet hemocyanin; MCI, mild cognitive impairment; PET, Positron emission tomography; pGlu, pyroglutamate, pyroglutamyl-; PiB, Pittsburgh compound B; PS-1, Presenilin 1; QC, Glutaminyl Cyclase.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors are grateful to Dr. Stephan Schilling, Fraunhofer Institute for Cell Therapy and Immunology for helpful comments during preparation of the manuscript.</p><sec id="FPar1"><title>Funding</title><p>This work was funded by the National Institutes of Health, NIH/NIA RO1 AG040092 to CAL.</p></sec><sec id="FPar2"><title>Authors&#8217; contributions</title><p>HC and CL designed the outline of the manuscript. HC, JF and HC wrote the manuscript. CL supervised, revised and edited the writing. All authors approved the final version of the manuscript.</p></sec><sec id="FPar3"><title>Competing interests</title><p>According to the journals requirements, we hereby declare that the first author, Holger Cynis, is a former employee of Probiodrug AG, Germany and he holds stock options of the company. Senior author, Cynthia A. Lemere, serves on Probiodrug AG&#8217;s Scientific Advisory Board and has received antibodies and unrestricted funding from Probiodrug AG for some her work on pGlu-3 A&#946; immunotherapy.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferri</surname><given-names>CP</given-names></name><name name-style="western"><surname>Prince</surname><given-names>M</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L</given-names></name><name name-style="western"><surname>Ganguli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Global prevalence of dementia: a Delphi consensus study</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>2112</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67889-0</pub-id><pub-id pub-id-type="pmid">16360788</pub-id><pub-id pub-id-type="pmcid">PMC2850264</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M, et al. World Alzheimer Report 2015, The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#8217;s disease: progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>NL</given-names></name><name name-style="western"><surname>Gatz</surname><given-names>M</given-names></name><name name-style="western"><surname>Berg</surname><given-names>S</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>B</given-names></name></person-group><article-title>How heritable is Alzheimer&#8217;s disease late in life? Findings from Swedish twins</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1002/ana.10999</pub-id><pub-id pub-id-type="pmid">14755721</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: genes, proteins, and therapy</article-title><source>Physiol Rev</source><year>2001</year><volume>81</volume><fpage>741</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">11274343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.2001.81.2.741</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miravalle</surname><given-names>L</given-names></name><name name-style="western"><surname>Calero</surname><given-names>M</given-names></name><name name-style="western"><surname>Takao</surname><given-names>M</given-names></name><name name-style="western"><surname>Roher</surname><given-names>AE</given-names></name><name name-style="western"><surname>Ghetti</surname><given-names>B</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>R</given-names></name></person-group><article-title>Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques</article-title><source>Biochemistry</source><year>2005</year><volume>44</volume><fpage>10810</fpage><lpage>10821</lpage><pub-id pub-id-type="doi">10.1021/bi0508237</pub-id><pub-id pub-id-type="pmid">16086583</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullan</surname><given-names>M</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>F</given-names></name><name name-style="western"><surname>Axelman</surname><given-names>K</given-names></name><name name-style="western"><surname>Houlden</surname><given-names>H</given-names></name><name name-style="western"><surname>Lilius</surname><given-names>L</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B</given-names></name><etal/></person-group><article-title>A pathogenic mutation for probable Alzheimer&#8217;s disease in the APP gene at the N-terminus of beta-amyloid</article-title><source>Nat Genet</source><year>1992</year><volume>1</volume><fpage>345</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/ng0892-345</pub-id><pub-id pub-id-type="pmid">1302033</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>T</given-names></name><name name-style="western"><surname>Dowjat</surname><given-names>WK</given-names></name><name name-style="western"><surname>Buxbaum</surname><given-names>JD</given-names></name><name name-style="western"><surname>Khorkova</surname><given-names>O</given-names></name><name name-style="western"><surname>Efthimiopoulos</surname><given-names>S</given-names></name><name name-style="western"><surname>Kulczycki</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer&#8217;s disease and leads to death as early as the age of 28 years</article-title><source>Neuroreport</source><year>1998</year><volume>9</volume><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1097/00001756-199801260-00008</pub-id><pub-id pub-id-type="pmid">9507958</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lemaire</surname><given-names>HG</given-names></name><name name-style="western"><surname>Unterbeck</surname><given-names>A</given-names></name><name name-style="western"><surname>Salbaum</surname><given-names>JM</given-names></name><name name-style="western"><surname>Masters</surname><given-names>CL</given-names></name><name name-style="western"><surname>Grzeschik</surname><given-names>KH</given-names></name><etal/></person-group><article-title>The precursor of Alzheimer&#8217;s disease amyloid A4 protein resembles a cell-surface receptor</article-title><source>Nature</source><year>1987</year><volume>325</volume><fpage>733</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/325733a0</pub-id><pub-id pub-id-type="pmid">2881207</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfe</surname><given-names>MS</given-names></name></person-group><article-title>The gamma-secretase complex: membrane-embedded proteolytic ensemble</article-title><source>Biochemistry</source><year>2006</year><volume>45</volume><fpage>7931</fpage><lpage>7939</lpage><pub-id pub-id-type="doi">10.1021/bi060799c</pub-id><pub-id pub-id-type="pmid">16800619</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vassar</surname><given-names>R</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>BD</given-names></name><name name-style="western"><surname>Babu-Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>S</given-names></name><name name-style="western"><surname>Mendiaz</surname><given-names>EA</given-names></name><name name-style="western"><surname>Denis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Beta-secretase cleavage of Alzheimer&#8217;s amyloid precursor protein by the transmembrane aspartic protease BACE</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1126/science.286.5440.735</pub-id><pub-id pub-id-type="pmid">10531052</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfe</surname><given-names>MS</given-names></name></person-group><article-title>Processive proteolysis by &#947;-secretase and the mechanism of Alzheimer&#8217;s disease</article-title><source>Biol Chem</source><year>2012</year><volume>393</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1515/hsz-2012-0140</pub-id><pub-id pub-id-type="pmid">22944690</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>H</given-names></name><name name-style="western"><surname>Takio</surname><given-names>K</given-names></name><name name-style="western"><surname>Ogawara</surname><given-names>M</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Mass spectrometry of purified amyloid beta protein in Alzheimer&#8217;s disease</article-title><source>J Biol Chem</source><year>1992</year><volume>267</volume><fpage>17082</fpage><lpage>17086</lpage><pub-id pub-id-type="pmid">1512246</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huse</surname><given-names>JT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Pijak</surname><given-names>DS</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>VM</given-names></name><name name-style="western"><surname>Doms</surname><given-names>RW</given-names></name></person-group><article-title>Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer&#8217;s disease brain</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>16278</fpage><lpage>16284</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111141200</pub-id><pub-id pub-id-type="pmid">11847218</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruninger-Leitch</surname><given-names>F</given-names></name><name name-style="western"><surname>Schlatter</surname><given-names>D</given-names></name><name name-style="western"><surname>Kung</surname><given-names>E</given-names></name><name name-style="western"><surname>Nelbock</surname><given-names>P</given-names></name><name name-style="western"><surname>Dobeli</surname><given-names>H</given-names></name></person-group><article-title>Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>4687</fpage><lpage>4693</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109266200</pub-id><pub-id pub-id-type="pmid">11741910</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenner</surname><given-names>GG</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CW</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</article-title><source>Biochem Biophys Res Commun</source><year>1984</year><volume>120</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(84)80190-4</pub-id><pub-id pub-id-type="pmid">6375662</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masters</surname><given-names>CL</given-names></name><name name-style="western"><surname>Simms</surname><given-names>G</given-names></name><name name-style="western"><surname>Weinman</surname><given-names>NA</given-names></name><name name-style="western"><surname>Multhaup</surname><given-names>G</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>BL</given-names></name><name name-style="western"><surname>Beyreuther</surname><given-names>K</given-names></name></person-group><article-title>Amyloid plaque core protein in Alzheimer disease and Down syndrome</article-title><source>Proc Natl Acad Sci U S A</source><year>1985</year><volume>82</volume><fpage>4245</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.12.4245</pub-id><pub-id pub-id-type="pmid">3159021</pub-id><pub-id pub-id-type="pmcid">PMC397973</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>CR</given-names></name><name name-style="western"><surname>Podlisny</surname><given-names>MB</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>LK</given-names></name></person-group><article-title>Isolation of Low-Molecular-Weight Proteins from Amyloid Plaque Fibers in Alzheimer&#8217;s Disease</article-title><source>J Neurochem</source><year>1986</year><volume>46</volume><fpage>1820</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1986.tb08501.x</pub-id><pub-id pub-id-type="pmid">3517233</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></name><name name-style="western"><surname>Mann</surname><given-names>DM</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>H</given-names></name><name name-style="western"><surname>Ihara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>S</given-names></name></person-group><article-title>Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques</article-title><source>Neuron</source><year>1995</year><volume>14</volume><fpage>457</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(95)90301-1</pub-id><pub-id pub-id-type="pmid">7857653</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawarabayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>LH</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>M</given-names></name><name name-style="western"><surname>Ashe</surname><given-names>KH</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>SG</given-names></name></person-group><article-title>Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer&#8217;s disease</article-title><source>J Neurosci</source><year>2001</year><volume>21</volume><fpage>372</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">11160418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.21-02-00372.2001</pub-id><pub-id pub-id-type="pmcid">PMC6763819</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Zeitschel</surname><given-names>U</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Heiser</surname><given-names>U</given-names></name><name name-style="western"><surname>Francke</surname><given-names>M</given-names></name><name name-style="western"><surname>Kehlen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer&#8217;s disease-like pathology</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>1106</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1038/nm.1872</pub-id><pub-id pub-id-type="pmid">18836460</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guntert</surname><given-names>A</given-names></name><name name-style="western"><surname>Dobeli</surname><given-names>H</given-names></name><name name-style="western"><surname>Bohrmann</surname><given-names>B</given-names></name></person-group><article-title>High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain</article-title><source>Neuroscience</source><year>2006</year><volume>143</volume><fpage>461</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.08.027</pub-id><pub-id pub-id-type="pmid">17008022</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>JL</given-names></name><name name-style="western"><surname>Le</surname><given-names>KX</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Ekpo</surname><given-names>E</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Palmour</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Pyroglutamate-3 amyloid-&#946; deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models</article-title><source>Am J Pathol</source><year>2013</year><volume>183</volume><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.05.005</pub-id><pub-id pub-id-type="pmid">23747948</pub-id><pub-id pub-id-type="pmcid">PMC3730768</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Manhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Demuth</surname><given-names>HU</given-names></name></person-group><article-title>Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions</article-title><source>FEBS Lett</source><year>2004</year><volume>563</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(04)00300-X</pub-id><pub-id pub-id-type="pmid">15063747</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Manhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wasternack</surname><given-names>C</given-names></name><name name-style="western"><surname>Demuth</surname><given-names>HU</given-names></name></person-group><article-title>Substrate specificity of glutaminyl cyclases from plants and animals</article-title><source>Biol Chem</source><year>2003</year><volume>384</volume><fpage>1583</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1515/BC.2003.175</pub-id><pub-id pub-id-type="pmid">14719800</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seifert</surname><given-names>F</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>K</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B</given-names></name><name name-style="western"><surname>Manhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Demuth</surname><given-names>H</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name></person-group><article-title>Glutaminyl cyclases display significant catalytic proficiency for glutamyl substrates</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>11831</fpage><lpage>11833</lpage><pub-id pub-id-type="doi">10.1021/bi9018835</pub-id><pub-id pub-id-type="pmid">19921850</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sevalle</surname><given-names>J</given-names></name><name name-style="western"><surname>Amoyel</surname><given-names>A</given-names></name><name name-style="western"><surname>Robert</surname><given-names>P</given-names></name><name name-style="western"><surname>Fourni&#233;-Zaluski</surname><given-names>M</given-names></name><name name-style="western"><surname>Roques</surname><given-names>B</given-names></name><name name-style="western"><surname>Checler</surname><given-names>F</given-names></name></person-group><article-title>Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide</article-title><source>J Neurochem</source><year>2009</year><volume>109</volume><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.05950.x</pub-id><pub-id pub-id-type="pmid">19187443</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citron</surname><given-names>M</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>T</given-names></name><name name-style="western"><surname>Capell</surname><given-names>A</given-names></name><name name-style="western"><surname>Haass</surname><given-names>C</given-names></name><name name-style="western"><surname>Teplow</surname><given-names>D</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D</given-names></name></person-group><article-title>Inhibition of Amyloid &#946;-Protein Production in Neural Cells by the Serine Protease Inhibitor AEBSF</article-title><source>Neuron</source><year>1996</year><volume>17</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(00)80290-1</pub-id><pub-id pub-id-type="pmid">8755488</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citron</surname><given-names>M</given-names></name><name name-style="western"><surname>Teplow</surname><given-names>DB</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Generation of amyloid &#946; protein from its precursor is sequence specific</article-title><source>Neuron</source><year>1995</year><volume>14</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(95)90323-2</pub-id><pub-id pub-id-type="pmid">7695913</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citron</surname><given-names>M</given-names></name><name name-style="western"><surname>Vigo-Pelfrey</surname><given-names>C</given-names></name><name name-style="western"><surname>Teplow</surname><given-names>DB</given-names></name><name name-style="western"><surname>Miller</surname><given-names>C</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>D</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>J</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B</given-names></name><name name-style="western"><surname>Venizelos</surname><given-names>N</given-names></name><name name-style="western"><surname>Lannfelt</surname><given-names>L</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation</article-title><source>Proc Natl Acad Sci U S A</source><year>1994</year><volume>91</volume><fpage>11993</fpage><lpage>11997</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.25.11993</pub-id><pub-id pub-id-type="pmid">7991571</pub-id><pub-id pub-id-type="pmcid">PMC45362</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Scheel</surname><given-names>E</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Demuth</surname><given-names>H</given-names></name></person-group><article-title>Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta</article-title><source>Biochemistry</source><year>2008</year><volume>47</volume><fpage>7405</fpage><lpage>7413</lpage><pub-id pub-id-type="doi">10.1021/bi800250p</pub-id><pub-id pub-id-type="pmid">18570439</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlenzig</surname><given-names>D</given-names></name><name name-style="western"><surname>Manhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Cinar</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Hause</surname><given-names>G</given-names></name><name name-style="western"><surname>Willbold</surname><given-names>D</given-names></name><etal/></person-group><article-title>Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>7072</fpage><lpage>7078</lpage><pub-id pub-id-type="doi">10.1021/bi900818a</pub-id><pub-id pub-id-type="pmid">19518051</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlenzig</surname><given-names>D</given-names></name><name name-style="western"><surname>R&#246;nicke</surname><given-names>R</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>H</given-names></name><name name-style="western"><surname>Scheel</surname><given-names>E</given-names></name><name name-style="western"><surname>Reymann</surname><given-names>K</given-names></name><etal/></person-group><article-title>N-Terminal pyroglutamate formation of A&#946;38 and A&#946;40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation</article-title><source>J Neurochem</source><year>2012</year><volume>121</volume><fpage>774</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07707.x</pub-id><pub-id pub-id-type="pmid">22375951</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nussbaum</surname><given-names>JM</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>E</given-names></name><name name-style="western"><surname>Wangsanut</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-&#946;</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>651</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/nature11060</pub-id><pub-id pub-id-type="pmid">22660329</pub-id><pub-id pub-id-type="pmcid">PMC3367389</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>C</given-names></name><name name-style="western"><surname>Violani</surname><given-names>E</given-names></name><name name-style="western"><surname>Salis</surname><given-names>S</given-names></name><name name-style="western"><surname>Venezia</surname><given-names>V</given-names></name><name name-style="western"><surname>Dolcini</surname><given-names>V</given-names></name><name name-style="western"><surname>Damonte</surname><given-names>G</given-names></name><etal/></person-group><article-title>Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival</article-title><source>J Neurochem</source><year>2002</year><volume>82</volume><fpage>1480</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01107.x</pub-id><pub-id pub-id-type="pmid">12354296</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandru</surname><given-names>A</given-names></name><name name-style="western"><surname>Jagla</surname><given-names>W</given-names></name><name name-style="western"><surname>Graubner</surname><given-names>S</given-names></name><name name-style="western"><surname>Becker</surname><given-names>A</given-names></name><name name-style="western"><surname>B&#228;uscher</surname><given-names>C</given-names></name><name name-style="western"><surname>Kohlmann</surname><given-names>S</given-names></name><etal/></person-group><article-title>Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A&#946; is induced by pyroglutamate-A&#946; formation</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>12790</fpage><lpage>12801</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1794-11.2011</pub-id><pub-id pub-id-type="pmid">21900558</pub-id><pub-id pub-id-type="pmcid">PMC6623394</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirths</surname><given-names>O</given-names></name><name name-style="western"><surname>Breyhan</surname><given-names>H</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Demuth</surname><given-names>H</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>TA</given-names></name></person-group><article-title>Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model</article-title><source>Acta Neuropathol</source><year>2009</year><volume>118</volume><fpage>487</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0557-5</pub-id><pub-id pub-id-type="pmid">19547991</pub-id><pub-id pub-id-type="pmcid">PMC2737116</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGowan</surname><given-names>E</given-names></name><name name-style="western"><surname>Pickford</surname><given-names>F</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Onstead</surname><given-names>L</given-names></name><name name-style="western"><surname>Eriksen</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Abeta42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice</article-title><source>Neuron</source><year>2005</year><volume>47</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2005.06.030</pub-id><pub-id pub-id-type="pmid">16039562</pub-id><pub-id pub-id-type="pmcid">PMC1373682</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Onstead</surname><given-names>L</given-names></name><name name-style="western"><surname>Randle</surname><given-names>S</given-names></name><name name-style="western"><surname>Price</surname><given-names>R</given-names></name><name name-style="western"><surname>Smithson</surname><given-names>L</given-names></name><name name-style="western"><surname>Zwizinski</surname><given-names>C</given-names></name><etal/></person-group><article-title>Abeta40 inhibits amyloid deposition in vivo</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>627</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4849-06.2007</pub-id><pub-id pub-id-type="pmid">17234594</pub-id><pub-id pub-id-type="pmcid">PMC6672801</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Gillman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>S</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>BL</given-names></name><name name-style="western"><surname>Nussinov</surname><given-names>R</given-names></name><etal/></person-group><article-title>Role of the fast kinetics of pyroglutamate-modified amyloid-&#946; oligomers in membrane binding and membrane permeability</article-title><source>Biochemistry</source><year>2014</year><volume>53</volume><fpage>4704</fpage><lpage>4714</lpage><pub-id pub-id-type="doi">10.1021/bi500587p</pub-id><pub-id pub-id-type="pmid">24950761</pub-id><pub-id pub-id-type="pmcid">PMC4215883</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>S</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>BL</given-names></name><name name-style="western"><surname>Nussinov</surname><given-names>R</given-names></name><etal/></person-group><article-title>Activity and Architecture of Pyroglutamate Modified Amyloid-&#946; (A&#946;pE3-42) Pores//Activity and architecture of pyroglutamate-modified amyloid-&#946; (A&#946;pE3-42) pores</article-title><source>J Phys Chem B</source><year>2014</year><volume>118</volume><fpage>7335</fpage><lpage>7344</lpage><pub-id pub-id-type="doi">10.1021/jp5040954</pub-id><pub-id pub-id-type="pmid">24922585</pub-id><pub-id pub-id-type="pmcid">PMC4096221</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunn</surname><given-names>AP</given-names></name><name name-style="western"><surname>Wong</surname><given-names>BX</given-names></name><name name-style="western"><surname>Johanssen</surname><given-names>T</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>JC</given-names></name><name name-style="western"><surname>Masters</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bush</surname><given-names>AI</given-names></name><etal/></person-group><article-title>Amyloid-&#946; Peptide A&#946;3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons</article-title><source>J Biol Chem</source><year>2016</year><volume>291</volume><fpage>6134</fpage><lpage>6145</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.655183</pub-id><pub-id pub-id-type="pmid">26697885</pub-id><pub-id pub-id-type="pmcid">PMC4813569</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schenk</surname><given-names>D</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>R</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>W</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>G</given-names></name><name name-style="western"><surname>Grajeda</surname><given-names>H</given-names></name><name name-style="western"><surname>Guido</surname><given-names>T</given-names></name><etal/></person-group><article-title>Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/22124</pub-id><pub-id pub-id-type="pmid">10408445</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemere</surname><given-names>CA</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E</given-names></name></person-group><article-title>Can Alzheimer disease be prevented by amyloid-beta immunotherapy?</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2009.219</pub-id><pub-id pub-id-type="pmid">20140000</pub-id><pub-id pub-id-type="pmcid">PMC2864089</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boche</surname><given-names>D</given-names></name><name name-style="western"><surname>Denham</surname><given-names>N</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>JA</given-names></name></person-group><article-title>Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer&#8217;s disease pathogenesis</article-title><source>Acta Neuropathol</source><year>2010</year><volume>120</volume><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0719-5</pub-id><pub-id pub-id-type="pmid">20632020</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilman</surname><given-names>S</given-names></name><name name-style="western"><surname>Koller</surname><given-names>M</given-names></name><name name-style="western"><surname>Black</surname><given-names>RS</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>L</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>SG</given-names></name><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000159740.16984.3C</pub-id><pub-id pub-id-type="pmid">15883316</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monsonego</surname><given-names>A</given-names></name><name name-style="western"><surname>Imitola</surname><given-names>J</given-names></name><name name-style="western"><surname>Zota</surname><given-names>V</given-names></name><name name-style="western"><surname>Oida</surname><given-names>T</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>HL</given-names></name></person-group><article-title>Microglia-Mediated Nitric Oxide Cytotoxicity of T Cells Following Amyloid -Peptide Presentation to Th1 Cells</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>2216</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.5.2216</pub-id><pub-id pub-id-type="pmid">12928365</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cribbs</surname><given-names>DH</given-names></name></person-group><article-title>Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid</article-title><source>Int Immunol</source><year>2003</year><volume>15</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxg049</pub-id><pub-id pub-id-type="pmid">12663680</pub-id><pub-id pub-id-type="pmcid">PMC1483061</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pride</surname><given-names>M</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>P</given-names></name><name name-style="western"><surname>Grundman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>M</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>J</given-names></name><name name-style="western"><surname>Black</surname><given-names>RS</given-names></name></person-group><article-title>Progress in the active immunotherapeutic approach to Alzheimer&#8217;s disease: clinical investigations into AN1792-associated meningoencephalitis</article-title><source>Neurodegener Dis</source><year>2008</year><volume>5</volume><fpage>194</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1159/000113700</pub-id><pub-id pub-id-type="pmid">18322388</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>C</given-names></name><name name-style="western"><surname>Boche</surname><given-names>D</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>D</given-names></name><name name-style="western"><surname>Yadegarfar</surname><given-names>G</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>V</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term effects of A&#946;42 immunisation in Alzheimer&#8217;s disease: follow-up of a randomised, placebo-controlled phase I trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61075-2</pub-id><pub-id pub-id-type="pmid">18640458</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Grundman</surname><given-names>M</given-names></name></person-group><article-title>Anti-amyloid-beta immunotherapy in Alzheimer&#8217;s disease: ACC-001 clinical trials are ongoing</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>17</volume><fpage>243</fpage><pub-id pub-id-type="pmid">19502708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2009-1118</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arai</surname><given-names>H</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></name><name name-style="western"><surname>Yoshiyama</surname><given-names>T</given-names></name></person-group><article-title>Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer&#8217; s Disease: Results from Two Phase 2 Studies</article-title><source>CAR</source><year>2015</year><volume>12</volume><fpage>242</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.2174/1567205012666150302154121</pub-id><pub-id pub-id-type="pmid">25731629</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winblad</surname><given-names>B</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N</given-names></name><name name-style="western"><surname>Minthon</surname><given-names>L</given-names></name><name name-style="western"><surname>Floesser</surname><given-names>A</given-names></name><name name-style="western"><surname>Imbert</surname><given-names>G</given-names></name><name name-style="western"><surname>Dumortier</surname><given-names>T</given-names></name><etal/></person-group><article-title>Safety, tolerability, and antibody response of active A&#946; immunotherapy with CAD106 in patients with Alzheimer&#8217;s disease: randomised, double-blind, placebo-controlled, first-in-human study</article-title><source>Lancet Neurol</source><year>2012</year><volume>11</volume><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70140-0</pub-id><pub-id pub-id-type="pmid">22677258</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farlow</surname><given-names>MR</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>M</given-names></name><name name-style="western"><surname>Vostiar</surname><given-names>I</given-names></name><name name-style="western"><surname>Vitaliti</surname><given-names>A</given-names></name><name name-style="western"><surname>Sovago</surname><given-names>J</given-names></name><etal/></person-group><article-title>Long-term treatment with active A&#946; immunotherapy with CAD106 in mild Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><year>2015</year><volume>7</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s13195-015-0108-3</pub-id><pub-id pub-id-type="pmid">25918556</pub-id><pub-id pub-id-type="pmcid">PMC4410460</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneeberger</surname><given-names>A</given-names></name><name name-style="western"><surname>Mandler</surname><given-names>M</given-names></name><name name-style="western"><surname>Otawa</surname><given-names>O</given-names></name><name name-style="western"><surname>Zauner</surname><given-names>W</given-names></name><name name-style="western"><surname>Mattner</surname><given-names>F</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>W</given-names></name></person-group><article-title>Development of AFFITOPE vaccines for Alzheimer&#8217;s disease (AD)--from concept to clinical testing</article-title><source>J Nutr Health Aging</source><year>2009</year><volume>13</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1007/s12603-009-0070-5</pub-id><pub-id pub-id-type="pmid">19262965</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson-Wood</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><name name-style="western"><surname>Motter</surname><given-names>R</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>G</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>R</given-names></name><etal/></person-group><article-title>Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>1550</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.4.1550</pub-id><pub-id pub-id-type="pmid">9037091</pub-id><pub-id pub-id-type="pmcid">PMC19829</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>S</given-names></name><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Raskind</surname><given-names>M</given-names></name><etal/></person-group><article-title>A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>2061</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c67808</pub-id><pub-id pub-id-type="pmid">19923550</pub-id><pub-id pub-id-type="pmcid">PMC2790221</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinne</surname><given-names>JO</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Rossor</surname><given-names>MN</given-names></name><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>R</given-names></name><name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></name><etal/></person-group><article-title>11C-PiB PET assessment of change in fibrillar amyloid-&#946; load in patients with Alzheimer&#8217;s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study//11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer&#8217;s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70043-0</pub-id><pub-id pub-id-type="pmid">20189881</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roher</surname><given-names>AE</given-names></name><name name-style="western"><surname>Cribbs</surname><given-names>DH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>RC</given-names></name><name name-style="western"><surname>Maarouf</surname><given-names>CL</given-names></name><name name-style="western"><surname>Whiteside</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kokjohn</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Bapineuzumab alters a&#946; composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e59735</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0059735</pub-id><pub-id pub-id-type="pmid">23555764</pub-id><pub-id pub-id-type="pmcid">PMC3605408</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farlow</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>SE</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Snider</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Porsteinsson</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Safety and biomarker effects of solanezumab in patients with Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2012</year><volume>8</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.09.224</pub-id><pub-id pub-id-type="pmid">22672770</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doody</surname><given-names>RS</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>RG</given-names></name><name name-style="western"><surname>Farlow</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B</given-names></name><name name-style="western"><surname>Joffe</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1312889</pub-id><pub-id pub-id-type="pmid">24450890</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siemers</surname><given-names>ER</given-names></name><name name-style="western"><surname>Sundell</surname><given-names>KL</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>C</given-names></name><name name-style="western"><surname>Case</surname><given-names>M</given-names></name><name name-style="western"><surname>Sethuraman</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu-Seifert</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer&#8217;s disease patients</article-title><source>Alzheimers Dement</source><year>2016</year><volume>12</volume><fpage>110</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2015.06.1893</pub-id><pub-id pub-id-type="pmid">26238576</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostrowitzki</surname><given-names>S</given-names></name><name name-style="western"><surname>Deptula</surname><given-names>D</given-names></name><name name-style="western"><surname>Thurfjell</surname><given-names>L</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Bohrmann</surname><given-names>B</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.1538</pub-id><pub-id pub-id-type="pmid">21987394</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemere</surname><given-names>CA</given-names></name><name name-style="western"><surname>Lopera</surname><given-names>F</given-names></name><name name-style="western"><surname>Kosik</surname><given-names>KS</given-names></name><name name-style="western"><surname>Lendon</surname><given-names>CL</given-names></name><name name-style="western"><surname>Ossa</surname><given-names>J</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><etal/></person-group><article-title>The E280A presenilin 1 Alzheimer mutation produces increased A&#946;42 deposition and severe cerebellar pathology</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>1146</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1038/nm1096-1146</pub-id><pub-id pub-id-type="pmid">8837617</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopera</surname><given-names>F</given-names></name><name name-style="western"><surname>Lopera</surname><given-names>F</given-names></name><name name-style="western"><surname>Ardilla</surname><given-names>A</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>A</given-names></name><name name-style="western"><surname>Madrigal</surname><given-names>L</given-names></name><name name-style="western"><surname>Arango-Viana</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation//Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation</article-title><source>JAMA</source><year>1997</year><volume>277</volume><fpage>793</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03540340027028</pub-id><pub-id pub-id-type="pmid">9052708</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhs</surname><given-names>A</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>DT</given-names></name><name name-style="western"><surname>Pihlgren</surname><given-names>M</given-names></name><name name-style="western"><surname>Chuard</surname><given-names>N</given-names></name><name name-style="western"><surname>Giriens</surname><given-names>V</given-names></name><name name-style="western"><surname>Meerschman</surname><given-names>C</given-names></name><etal/></person-group><article-title>Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>9810</fpage><lpage>9815</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703137104</pub-id><pub-id pub-id-type="pmid">17517595</pub-id><pub-id pub-id-type="pmcid">PMC1887581</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adolfsson</surname><given-names>O</given-names></name><name name-style="western"><surname>Pihlgren</surname><given-names>M</given-names></name><name name-style="western"><surname>Toni</surname><given-names>N</given-names></name><name name-style="western"><surname>Varisco</surname><given-names>Y</given-names></name><name name-style="western"><surname>Buccarello</surname><given-names>AL</given-names></name><name name-style="western"><surname>Antoniello</surname><given-names>K</given-names></name><etal/></person-group><article-title>An effector-reduced anti-&#946;-amyloid (A&#946;) antibody with unique a&#946; binding properties promotes neuroprotection and glial engulfment of A&#946;</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>9677</fpage><lpage>9689</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4742-11.2012</pub-id><pub-id pub-id-type="pmid">22787053</pub-id><pub-id pub-id-type="pmcid">PMC6622286</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haass</surname><given-names>C</given-names></name><name name-style="western"><surname>Schlossmacher</surname><given-names>MG</given-names></name><name name-style="western"><surname>Hung</surname><given-names>AY</given-names></name><name name-style="western"><surname>Vigo-Pelfrey</surname><given-names>C</given-names></name><name name-style="western"><surname>Mellon</surname><given-names>A</given-names></name><name name-style="western"><surname>Ostaszewski</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Amyloid beta-peptide is produced by cultured cells during normal metabolism</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>322</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1038/359322a0</pub-id><pub-id pub-id-type="pmid">1383826</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niederwolfsgruber</surname><given-names>E</given-names></name><name name-style="western"><surname>Schmitts</surname><given-names>TL</given-names></name><name name-style="western"><surname>Blasko</surname><given-names>I</given-names></name><name name-style="western"><surname>Trieb</surname><given-names>K</given-names></name><name name-style="western"><surname>Steger</surname><given-names>MM</given-names></name><name name-style="western"><surname>Maczek</surname><given-names>C</given-names></name><etal/></person-group><article-title>The Production of the Alzheimer Amyloid Precursor Protein (APP) in Extraneuronal Tissue Does Not Increase in Old Age</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>1998</year><volume>53</volume><fpage>B186</fpage><lpage>B190</lpage><pub-id pub-id-type="doi">10.1093/gerona/53A.3.B186</pub-id><pub-id pub-id-type="pmid">9597042</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mawuenyega</surname><given-names>KG</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>W</given-names></name><name name-style="western"><surname>Ovod</surname><given-names>V</given-names></name><name name-style="western"><surname>Munsell</surname><given-names>L</given-names></name><name name-style="western"><surname>Kasten</surname><given-names>T</given-names></name><name name-style="western"><surname>Morris</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Decreased clearance of CNS beta-amyloid in Alzheimer&#8217;s disease</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>1774</fpage><pub-id pub-id-type="doi">10.1126/science.1197623</pub-id><pub-id pub-id-type="pmid">21148344</pub-id><pub-id pub-id-type="pmcid">PMC3073454</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soscia</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>JE</given-names></name><name name-style="western"><surname>Washicosky</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ingelsson</surname><given-names>M</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B</given-names></name><etal/></person-group><article-title>The Alzheimer&#8217;s disease-associated amyloid beta-protein is an antimicrobial peptide</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e9505</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0009505</pub-id><pub-id pub-id-type="pmid">20209079</pub-id><pub-id pub-id-type="pmcid">PMC2831066</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plant</surname><given-names>LD</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>JP</given-names></name><name name-style="western"><surname>Smith</surname><given-names>IF</given-names></name><name name-style="western"><surname>Peers</surname><given-names>C</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>HA</given-names></name></person-group><article-title>The production of amyloid beta peptide is a critical requirement for the viability of central neurons</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><fpage>5531</fpage><lpage>5535</lpage><pub-id pub-id-type="pmid">12843253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.23-13-05531.2003</pub-id><pub-id pub-id-type="pmcid">PMC6741264</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Frost JL, Liu B, Shi Q, Kleinschmidt M, Demuth HU, Schilling S, Lemere CA. Passive and active pyroglutamate-3 Abeta (AbetaN3pE) immunotherapy in AD-like transgenic mouse models: Abstract Society for Neuroscience. 2010</mixed-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acero</surname><given-names>G</given-names></name><name name-style="western"><surname>Manoutcharian</surname><given-names>K</given-names></name><name name-style="western"><surname>Vasilevko</surname><given-names>V</given-names></name><name name-style="western"><surname>Munguia</surname><given-names>ME</given-names></name><name name-style="western"><surname>Govezensky</surname><given-names>T</given-names></name><name name-style="western"><surname>Coronas</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits</article-title><source>J Neuroimmunol</source><year>2009</year><volume>213</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2009.06.003</pub-id><pub-id pub-id-type="pmid">19545911</pub-id><pub-id pub-id-type="pmcid">PMC2725226</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardberg</surname><given-names>AS</given-names></name><name name-style="western"><surname>Dice</surname><given-names>LT</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S</given-names></name><name name-style="western"><surname>Rich</surname><given-names>RL</given-names></name><name name-style="western"><surname>Helmbrecht</surname><given-names>E</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J</given-names></name><etal/></person-group><article-title>Molecular basis for passive immunotherapy of Alzheimer&#8217;s disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>15659</fpage><lpage>15664</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705888104</pub-id><pub-id pub-id-type="pmid">17895381</pub-id><pub-id pub-id-type="pmcid">PMC1994138</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirths</surname><given-names>O</given-names></name><name name-style="western"><surname>Erck</surname><given-names>C</given-names></name><name name-style="western"><surname>Martens</surname><given-names>H</given-names></name><name name-style="western"><surname>Harmeier</surname><given-names>A</given-names></name><name name-style="western"><surname>Geumann</surname><given-names>C</given-names></name><name name-style="western"><surname>Jawhar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>41517</fpage><lpage>41524</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.178707</pub-id><pub-id pub-id-type="pmid">20971852</pub-id><pub-id pub-id-type="pmcid">PMC3009878</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>JL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Demuth</surname><given-names>H</given-names></name><name name-style="western"><surname>Lemere</surname><given-names>CA</given-names></name></person-group><article-title>Passive immunization against pyroglutamate-3 amyloid-&#946; reduces plaque burden in Alzheimer-like transgenic mice: a pilot study</article-title><source>Neurodegener Dis</source><year>2012</year><volume>10</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1159/000335913</pub-id><pub-id pub-id-type="pmid">22343072</pub-id><pub-id pub-id-type="pmcid">PMC3702016</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>JL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Rahfeld</surname><given-names>JU</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Nuallain</surname><given-names>B</given-names></name><name name-style="western"><surname>Le</surname><given-names>KX</given-names></name><etal/></person-group><article-title>An anti-pyroglutamate-3 Abeta vaccine reduces plaques and improves cognition in APPswe/PS1DeltaE9 mice</article-title><source>Neurobiol Aging</source><year>2015</year><volume>36</volume><fpage>3187</fpage><lpage>3199</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.08.021</pub-id><pub-id pub-id-type="pmid">26453001</pub-id><pub-id pub-id-type="pmcid">PMC4641825</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Crehan</surname><given-names>H</given-names></name><name name-style="western"><surname>Rahfeld</surname><given-names>JU</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Le</surname><given-names>KX</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Nuallain</surname><given-names>B</given-names></name><etal/></person-group><source>Anti-pGlu Abeta mAb Ig isotype affects plaque clearance.: Abstract</source><year>2015</year></element-citation></ref><ref id="CR80"><label>80.</label><mixed-citation publication-type="other">Crehan H, Kleinschmidt M, Fitzpatrick E, Chowdhury S, Le KX, Frost JL, et al. Passive vaccination targeting pyroglutamate-3 Abeta reduces Abeta plaque burden without microhemorrhage and partially rescues cognitive deficits in aged APP/PS1/dE9 mice: Abstract. Soc Neurosci. 2015.</mixed-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lemere</surname><given-names>CA</given-names></name><name name-style="western"><surname>Crehan</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahfeld</surname><given-names>JU</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>E</given-names></name><etal/></person-group><source>Phagocytic characterization and therapeutic efficacy of an anti-pyroglutamate-3 Abeta IgG2a antibody in aged APP/PS1dE9 mice: Abstract</source><year>2016</year></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeifer</surname><given-names>M</given-names></name><name name-style="western"><surname>Boncristiano</surname><given-names>S</given-names></name><name name-style="western"><surname>Bondolfi</surname><given-names>L</given-names></name><name name-style="western"><surname>Stalder</surname><given-names>A</given-names></name><name name-style="western"><surname>Deller</surname><given-names>T</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cerebral hemorrhage after passive anti-Abeta immunotherapy</article-title><source>Science</source><year>2002</year><volume>298</volume><fpage>1379</fpage><pub-id pub-id-type="doi">10.1126/science.1078259</pub-id><pub-id pub-id-type="pmid">12434053</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMattos</surname><given-names>RB</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Racke</surname><given-names>MM</given-names></name><name name-style="western"><surname>Delong</surname><given-names>CA</given-names></name><name name-style="western"><surname>Tzaferis</surname><given-names>JA</given-names></name><etal/></person-group><article-title>A plaque-specific antibody clears existing &#946;-amyloid plaques in Alzheimer&#8217;s disease mice</article-title><source>Neuron</source><year>2012</year><volume>76</volume><fpage>908</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.10.029</pub-id><pub-id pub-id-type="pmid">23217740</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Wakabayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>A</given-names></name><name name-style="western"><surname>Kowa</surname><given-names>H</given-names></name><name name-style="western"><surname>Hosoda</surname><given-names>R</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>A</given-names></name><etal/></person-group><article-title>CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><fpage>1524</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1093/emboj/21.7.1524</pub-id><pub-id pub-id-type="pmid">11927537</pub-id><pub-id pub-id-type="pmcid">PMC125364</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>